Cardiovascular Disease
Epidemiology of Cholesterol and Cardiovascular Disease
Lipid and Lipoprotein Basics
Clinical Lipid Management
An avocado a day may improve diet quality, sleep
CHICAGO — Daily avocado intake for half a year did not significantly improve overall cardiovascular health, but it was associated with improvements in certain components, research presented at NUTRITION showed.
Combined SGLT2 and GLP-1 therapy lowers risk for CVD, kidney disease in type 2 diabetes
Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology.
Half of US counties, mostly rural, lack any cardiologists
Nearly half of U.S. counties lack cardiologists, almost all of which are rural, with lower household income and higher prevalence of CV risk factors, according to a research letter published in the Journal of the American College of Cardiology.
Mediterranean diet associated with lower risk for death in cancer survivors
Adopting the Mediterranean diet after receiving a cancer diagnosis improved survival outcomes, according to observational study results published in JACC: CardioOncology.
Intensive therapy may blunt higher CVD risk for younger women with hypertension, diabetes
Women with type 2 diabetes diagnosed with hypertension at younger than age 50 years have an increased risk for cardiovascular disease and could benefit from intensive antihypertension therapy according to data published in Diabetes Care.
These diets could reduce CVD risk for adults with type 1 diabetes
CHICAGO — For adults with type 1 diabetes, the Mediterranean and DASH diets could help reduce the risk for CVD, according to research presented at NUTRITION.
SELECT: Semaglutide provides CV benefits for adults with obesity, regardless of HbA1c
ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.